CALC Stock Analysis: Buy, Sell, or Hold?
CALC - CalciMedica, Inc. Common Stock
$2.29
1.83 (393.41%)
▲
5d:
+311.83%
30d:
+129.14%
90d:
+172.14%
WAIT
LOW Confidence
Analysis Updated: Aug 28, 2026 12:00 AM ET
Earnings: Aug 11, 2026
0d
Get Alerted When CALC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: CALC is 193.8% above its trading range ($0.78). While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: CALC is 193.8% above its trading range ($0.78). While momentum could continue, risk/reward favors waiting for a pullback.
In-depth Analysis How we analyze
Valuation Analysis: CALC is currently trading at $2.29, which is considered oversold relative to its 30-day fair value range of $0.57 to $0.78.
Technical Outlook: Technically, CALC is showing sideways momentum. The price is approaching resistance at $0.69. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 393.4% recently.
Market Sentiment: CALC scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $10.00 (+2053.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CALC is showing sideways momentum. The price is approaching resistance at $0.69. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 393.4% recently.
Market Sentiment: CALC scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $10.00 (+2053.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.57 -
$0.78
Company Quality Score
44/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (33/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+393.4%)
- BULLISH: Trading 2053.3% below Wall St target ($10.00)
- WARNING: Composite score 44/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.57 -
$0.78
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.44
Resistance Level
$0.69
Current Trend
Sideways
Technical data as of
Aug 28, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.44
Wall Street Target
$10.00
(+2053.3%)
Share & Embed Analysis
Last updated: August 31, 2026 12:18 PM ET
Data refreshes hourly during market hours. Next update: 1:18 PM
Data refreshes hourly during market hours. Next update: 1:18 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CALC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 38 SELL |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$840 | 46 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$287 | 60 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$29 | 53 HOLD |
|
ACAD
ACADIA Pharmaceuticals I… |
BUY
20 analysts |
$34 | 49 HOLD |
